Article
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Science immunology - 21 Feb 2020
Lu Tianshi, Wang Shidan, Xu Lin, Zhou Qinbo, Singla Nirmish, Gao Jianjun, Manna Subrata, Pop Laurentiu, Xie Zhiqun, Chen Mingyi, Luke Jason J, Brugarolas James, Hannan Raquibul, Wang Tao
Abstract excerpt
Lack of responsiveness to checkpoint inhibitors is a central problem in the modern era of cancer immunotherapy. Tumor neoantigens are critical targets of the host antitumor immune response, and their presence correlates with the efficacy of immunotherapy treatment. Many studies involving assessment of tumor neoantigens principally focus on total neoantigen load, which simplistically treats all neoantigens...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.